Definitive Healthcare (NASDAQ:DH) Releases Q3 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its third quarter 2026 earnings guidance on Monday morning. The company provided EPS guidance of 0.040-0.050 for the period, compared to the consensus earnings per share estimate of 0.040. The company issued revenue guidance of $54.0 million-$55.0 million, compared to the consensus revenue estimate of $55.5 million. Definitive Healthcare also updated its FY 2026 guidance to 0.180-0.200 EPS.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Bank of America restated an “underperform” rating and issued a $0.70 price objective on shares of Definitive Healthcare in a research note on Monday, June 29th. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Finally, Robert W. Baird set a $1.10 target price on Definitive Healthcare in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $1.88.

Definitive Healthcare Stock Performance

Shares of DH stock traded down $0.01 during mid-day trading on Monday, hitting $0.70. The stock had a trading volume of 172,029 shares, compared to its average volume of 358,377. The firm has a market cap of $73.71 million, a PE ratio of -0.43, a PEG ratio of 11.51 and a beta of 1.35. The company’s 50-day simple moving average is $0.78 and its 200-day simple moving average is $1.12. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. Definitive Healthcare has a fifty-two week low of $0.62 and a fifty-two week high of $4.35.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $55.93 million during the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Sell-side analysts anticipate that Definitive Healthcare will post 0.04 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new stake in shares of Definitive Healthcare in the 2nd quarter valued at approximately $32,000. Schonfeld Strategic Advisors LLC acquired a new position in Definitive Healthcare during the fourth quarter worth $35,000. HRT Financial LP acquired a new position in Definitive Healthcare during the fourth quarter worth $47,000. ExodusPoint Capital Management LP purchased a new position in Definitive Healthcare in the fourth quarter worth $47,000. Finally, Bayesian Capital Management LP acquired a new stake in Definitive Healthcare in the second quarter valued at $55,000. 98.67% of the stock is owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.